1 / 39

Management of Testicular Tumours

Management of Testicular Tumours. Dr.Sunil Shroff, MS, FRCS (UK ), D.Urol (Lond.) Prof & HOD SriRamachandra Medical College & Research Institution, Chennai . TESTICULAR TUMOUR. 1% of all Malignant Tumour Affects young adults - 20 to 40 yrs - when Testosterone Fluctuations are maximum

lovey
Download Presentation

Management of Testicular Tumours

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Management of Testicular Tumours Dr.Sunil Shroff, MS, FRCS (UK ), D.Urol (Lond.) Prof & HOD SriRamachandra Medical College & Research Institution, Chennai

  2. TESTICULAR TUMOUR 1% of all Malignant Tumour Affects young adults - 20 to 40 yrs - when Testosterone Fluctuations are maximum 90% to 95% of all Testicular tumours from germ cells 99% of all Testicular Tumours are malignant. Causes Psychological & Fertility Problems in young

  3. Survival in Testicular Tumours Improved overall survival in last 15 to 20 years due to - • Better understanding of Natural History and Pathogenesis of disease • Reliable Tumour Markers • Cis-platinum based chemotherapy

  4. CROSS SECTION OF TESTIS Testis Stroma Seminiferous Tubules (200 to 350 tubules) Interstitial Cells Supporting Spermatogonia Leydig or (Androgen) Sertoli Cell

  5. EPIDEMIOLOGY Incidence : 1.2 per 100,000 (Bombay) 3.7 per 100,000 (USA) Age : 3 Peaks - 20-40 yrs. Maximum - 0 - 10 yrs. - After - 60 yrs. Bilaterality : 2 to 3% Testicular Tumour

  6. CLASSIFICATION I. Primary Neoplasma of Testis. A. Germ Cell Tumour B. Non-Germ Cell Tumour II. Secondary Neoplasms. III. Paratesticular Tumours.

  7. I. PRIMARY NEOPLASMS OF TESTIS A. Germinal Neoplasms : (90 - 95 %) 1. Seminomas - 40% (a) Classic Typical Seminoma (b) Anaplastic Seminoma (c) Spermatocytic Seminoma 2. Embryonal Carcinoma - 20 - 25% 3. Teratoma - 25 - 35% (a) Mature (b) Immature 4. Choriocarcinoma - 1% 5. Yolk Sac Tumour

  8. I. PRIMARY NEOPLASMS OF TESTIS B. Nongerminal Neoplasms : ( 5 to 10% ) 1. Specialized gonadal stromal tumor (a) Leydig cell tumor (b) Other gonadal stromal tumor 2. Gonadoblastoma 3. Miscellaneous Neoplasms (a) Adenocarcinoma of the rete testis (b) Mesenchymal neoplasms (c) Carcinoid (d) Adrenal rest “tumor”

  9. II. SECONDARY NEOPLASMS OF TESTIS A. Reticuloendothelial Neoplasms B. Metastases III. PARATESTICULAR NEOPLASMS A. Adenomatoid B. Cystadenoma of Epididymis C. Mesenchymal Neoplasms D. Mesothelioma E. Metastases

  10. AETIOLOGY OF TESTICULAR TUMOUR 1. Cryptorchidism 2. Carcinoma in situ 3. Trauma 4. Atrophy

  11. CRYPTORCHIDISM & TESTICULAR TUMOUR Risk of Carcinoma developing in undescended testis is 14 to 48 times the normal expected incidence

  12. CRYPTORCHIDISM & TESTICULAR TUMOUR The cause for malignancy are as follows: • Abnormal Germ Cell Morphology • Elevated temperature in abdomen & Inguinal region as opposed to scrotum • Endocrinal disturbances • Gonadal dysgenesis

  13. Testicular Tumour & Molecular Biology (Recent Advances) Molecular & Genetic Research may help Future patient with Testicular Tumours: Earlier diagnosis Identify Susceptible Individuals

  14. Testicular Tumour & Molecular Biology PROTO-ONCOGENES in Germ Cell Tumours (Shuin et al) Seminoma & Embryonal - N-myc expression Carcinoma Seminoma - c-Ki-ras expression Immature Teratomas - c-erb B-1 expression

  15. Testicular Tumour & Molecular Biology (Recent Advances) Testicular germ cell tumour show consistent expression of both: • Parental alleles of H19 • IGF-2 genes.

  16. Clinical Staging of Testicular Tumour Staging A or I - Tumour confined to testis. Staging B or II - Spread to Regional nodes. IIA - Nodes <2 cm in size or < 6 Positive Nodes IIB - 2 to 5 cm in size or > 6 Positive Nodes IIC - Large, Bulky, abd.mass usually > 5 to 10 cm Staging C or III - Spread beyond retroperitoneal Nodes or Above Diaphragm or visceral disease

  17. Requirements for staging To properly Stage Testicular Tumours following are pre-requisites: (a) Pathology of Tumour Specimen (b) History (c) Clinical Examination (d) Radiological procedure - USG / CT / MRI / Bone Scan (e) Tumour Markers -  HCG, AFP

  18. TNM Staging of Testicular Tumour T0 = No evidence of Tumour T1s = Intratubular, pre invasive T1 = Confined to Testis T2 = Invades beyond Tunica Albuginea or into Epididymis T3 = Invades Spermatic Cord T4 = Invades Scrotum N1 = Single < 2 cm N2 = Multiple < 5 cm / Single 2-5 cm N3 = Any node > 5 cm Epididymis or Scrotal skin – Lymph drainage to Inguinal Nodes

  19. Pathogenesis & Natural History of Testicular Tumour Course of Spread of Germ Cell Tumours are predictible once Histology of Tumour cofirmed Lymphatic Spread has a set pattern depending on side of Tumour Seminoma may have non-seminomatous metastasis High Grade Tumours spread by both Vascular invasion & via Lymphatics

  20. Investigation 1. Ultrasound - Hypoechoic area 2. Chest X-Ray - PA and lateral views 3. CT Scan 4. Tumour Markers - AFP -  HCG - LDH - PLAP

  21. CLINICAL FEATURES • Painless Swelling of One Gonad • Dull Ache or Heaviness in Lower Abdomen • 10% - Acute Scrotal Pain • 10% - Present with Metatstasis - Neck Mass / Cough / Anorexia / Vomiting / Back Ache/ Lower limb swelling • 5% - Gynecomastia • Rarely - Infertility

  22. DICTUM FOR ANY SOLID SCROTAL SWELLINGS All patients with a solid, Firm Intratesticular Mass that cannot be Transilluminated should be regarded as Malignant unless otherwise proved

  23. Tumour Markers TWO MAIN CLASSES • Onco-fetal Substances : AFP & HCG • Cellular Enzymes : LDH & PLAP ( AFP - Trophoblastic Cells HCG - Syncytiotrophoblastic Cells )

  24. AFP –( Alfafetoprotein ) NORMAL VALUE: Below 16 ngm / ml HALF LIFE OF AFP – 5 and 7 days Raised AFP : • Pure embryonal carcinoma • Teratocarcinoma • Yolk sac Tumour • Combined Tumour REMEMBER: AFP Not raised is Pure Choriocarcinoma or Pure Seminoma

  25. HCG – ( Human Chorionic Gonadotropin ) Has  and  polypeptide chain NORMAL VALUE: < 1 ng / ml HALF LIFE of HCG: 24 to 36 hours RAISED  HCG - 100 % - Choriocarcinoma 60% - Embryonal carcinoma 55% - Teratocarcinoma\ 25% - Yolk Cell Tumour 7% - Seminomas

  26. ROLE OF TUMOUR MARKERS • Helps in Diagnosis - 80 to 85% of Testicular Tumours have Positive Markers • Most of Non-Seminomas have raised markers • Only 10 to 15% Non-Seminomas have normal marker level • After Orchidectomy if Markers Elevated means Residual Disease or Stage II or III Disease • Elevation of Markers after Lymphadenectomy means a STAGE III Disease

  27. ROLE OF TUMOUR MARKERS cont... • Degree of Marker Elevation Appears to be Directly Proportional to Tumour Burden • Markers indicate Histology of Tumour: If AFP elevated in Seminoma - Means Tumour has Non-Seminomatous elements • Negative Tumour Markers becoming positive on follow up usually indicates - Recurrence of Tumour • Markers become Positive earlier than X-Ray studies

  28. PRINCIPLES OF TREATMENT • Treatment should be aimed at one stage above the clinical stage • Seminomas - Radio-Sensitive. Treat with Radiotherapy. • Non-Seminomas are Radio-Resistant and best treated by Surgery • Advanced Disease or Metastasis - Responds well to Chemotherapy

  29. PRINCIPLES OF TREATMENT • Radical INGUINAL ORCHIDECTOMY is Standard first line of therapy • Lymphatic spread initially goes to RETRO-PERITONEAL NODES • Early hematogenous spread RARE • Bulky Retroperitoneal Tumours or Metastatic Tumors Initially “DOWN-STAGED” with CHEMOTHERAPY

  30. Treatment of Seminomas Stage I, IIA, ?IIB – Radical Inguinal Orichidectomy followed by radiotherapy to Ipsilateral Retroperitonium & Ipsilateral Iliac group Lymph nodes (2500-3500 rads) Bulky stage II and III Seminomas - Radical Inguinal Orchidectomy is followed by Chemotherapy

  31. Treatment of Non-Seminoma Stage I and IIA: RADICAL ORCHIDECTOMY followed by RETROPERITONEAL LYMPH NODES DISSECTION Stage IIB: RPLND with possible ADJUVANT CHEMOTHERAPY Stage IIC and Stage III Disease: Initial CHEMOTHERAPY followed by SURGERY for Residual Disease

  32. STANDARD CHEMOTHERAPY FOR NON-SEMINOMATOUS GERM CELL TUMOURS Chemotherapy Toxicity BEP - Bleomycin Pulmonary fibrosis Etoposide (VP-16) Myelosuppression Alopecia Renal insufficiency (mild) Secondary leukemia Cis-platin Renal insufficiency Nausea, vomiting Neuropathy

  33. Left Right Axial CT Section demonstarating - Left Hydronephrosis, due to large Para-Aortic Nodal Mass from a Germ cell tumour

  34. Limits of Lymph Nodes Dissection For Right & Left Sided Testicular Tumours

  35. THERAPY OF PATIENT WITH SEMINOMA Stage I, IIA, ? IIBStage IIB, IIC, III B - Bleomycin Abdominal Radiotherapy E - Etoposide (VP-16)  4 cycles P - cis-platin Follow UpStable/Regress Relapse/Growth F/U ? RPLND ? Chemotherapy ? XRT

  36. Therapy of Nonseminomatous Germ Cell Testicular Tumours Radical Inguinal Orchidectomy Stage I, II (minimum) RPLND Stage I, II B1 Stage II B2 Observe BEP  2 cycles Bleomycin Etoposide Cis-platin

  37. Therapy of Nonseminomatous Germ Cell Testicular Tumours Radical Inguinal Orchidectomy Stage II C (advanced) / III BEP  4 cycles Complete Response Partial Response Progress Observe RPLND VIP or Autologous Bone marrow Transplant Cancer Teratoma / Fibrosis V-Vinblastine I-Ifosfamide OBSERVE P-cis-platin

  38. PROGNOSIS Seminoma Nonseminoma Stage I 99% 95% to 99% Stage II 70% to 92% 90% Stage III 80% to 85% 70% to 80%

  39. CONCLUSION • Improved Overall Survival of Testicular Tumour due to Better Understanding of the Disease, Tumour Markers and Cis-platinum based Chemotherapy • Current Emphasis is on Diminishing overall Morbidity of Various Treatment Modalities

More Related